Needham Maintains Buy on Mereo BioPharma Group, Lowers Price Target to $5
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Needham analyst Gil Blum maintains Mereo BioPharma Group (NASDAQ:MREO) with a Buy and lowers the price target from $7 to $5.
Needham analyst Gil Blum maintains Mereo BioPharma Group (NASDAQ:MREO) with a Buy and lowers the price target from $7 to $5.